Anzeige
Mehr »
Login
Dienstag, 19.03.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Mega-Kurskatalysator - Vorbereitung der Phase-3 Studie soeben bestätigt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DTUW | ISIN: US6960775020 | Ticker-Symbol: PTN
Tradegate
19.03.24
10:46 Uhr
1,470 Euro
-0,020
-1,34 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PALATIN TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
PALATIN TECHNOLOGIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,4601,51012:45
1,4601,51012:33

Aktuelle News zur PALATIN TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoPALATIN TECHNOLOGIES INC - S-1, General form for registration of securities23
29.02.Palatin pummelled as dry eye therapy underwhelms in phase 382
28.02.Palatin slumps as dry-eye drug fails to meet one of the main goals in study46
28.02.Palatin CEO claims 'a positive study on its face,' despite dry eye drug's primary endpoint miss37
28.02.Palatin stock plunges 40% on mixed Phase 3 data for dry eye drug25
28.02.Palatin Stock Drops As Co-Primary Sign, Secondary Sign Endpoints Not Met In PL9643 Phase 3 DED Trial22
28.02.Palatin Technologies: Aktie schmiert ab - das steckt dahinter1.350Palatin hat am Mittwochmittag Studienergebnisse zu einem Medikament gegen Augentrockenheit veröffentlicht. Die Aktie schmiert daraufhin ab.Palatin Technologies, ein Unternehmen aus dem biopharmazeutischen...
► Artikel lesen
28.02.Pre-market Movers: Bit Brother, Beyond Meat, Oragenics, Palatin Technologies, Integral Ad Science568PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.10 A.M. ET).In the Green Bit Brother Limited (BETS) is up over 68%...
► Artikel lesen
28.02.Palatin Technologies, Inc.: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)371On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P Multiple Secondary Symptom Endpoints Met, Statistical Significance (P On an Intent-to-Treat Analysis...
► Artikel lesen
16.02.Earnings call: Palatin highlights strategic focus and reports Q2 results67
15.02.PALATIN TECHNOLOGIES INC - 8-K, Current Report36
15.02.Palatin Technologies Inc. Q2 Earnings Summary418WASHINGTON (dpa-AFX) - Below are the earnings highlights for Palatin Technologies Inc. (PTN):Earnings: -$7.84 million in Q2 vs. $2.71 million in the same period last year. EPS: -$0.56 in Q2...
► Artikel lesen
15.02.Palatin Tech GAAP EPS of -$0.56 misses by $0.23, revenue of $2.03M beats by $0.27M28
15.02.Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update295Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED)- Topline Data Expected in February Oral...
► Artikel lesen
14.02.Earnings Preview: Palatin Techs31
05.02.Palatin Technologies, Inc.: Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)610Top-Line Results Expected in February CRANBURY, N.J., Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines...
► Artikel lesen
01.02.PALATIN TECHNOLOGIES INC - 8-K, Current Report42
30.01.Palatin Technologies Prices Offering Of $10 Mln Of Shares; Stock Down Over 4% In Pre-Market450WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN), a biopharmaceutical company, said on Tuesday that it has inked a deal with institutional investors for the issuance and sale of its 1...
► Artikel lesen
30.01.Palatin to raise ~$10M via securities offering34
08.01.Palatin gears up for multiple clinical trial readouts in 202496
Seite:  Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
9,1,117